Noerr advises Silverfleet Capital on the sale of Aesica Pharmaceuticals

14.10.2014

The law firm Noerr with a team led by Dr. Georg Schneider and Dr. Tobias Koppmann advised the European investment company Silverfleet Capital (London) on the sale of Aesica Pharmaceuticals. Silverfleet Capital is selling Aesica for approx. 290 million Euro to the listed Consort Medical plc., an international healthcare company. In 2011, a Noerr team led by Georg Schneider previously acted as legal advisor to Silverfleet Capital on the acquisition of Aesica.

Aesica Pharmaceuticals with approx. 1,250 employees is one of Europe’s leading pharmaceutical CDMOs, providing contract development and manufacturing services for finished dose and active pharmaceutical ingredients (APIs) to the global pharmaceutical industry with sites in the UK, Germany and Italy. In Germany, Aesica has development and production facilities in Monheim and Zwickau. The completion of the transaction is subject to the approval by the German Federal Cartel Office and the Consort Medical shareholders.

The Noerr team advised Silverfleet Capital on the German law aspects of the transaction under the international leadership of Travers Smith.

Advisor Silverfleet Capital: Noerr LLP

Dr. Georg Schneider, Dr. Tobias Koppmann (both Private Equity, Munich), Sebastian Bock (finance, Frankfurt), Marco Winterer (real estate, Munich), Evelyn Schulz (health care, Dresden), Dr. Wolfgang Schelling (employment), Dr. Sebastian Janka (regulatory, both Munich)

Associates: Ethel Nanaeva (corporate, Munich), Dr. Bettina Röder (finance, Frankfurt), Dr. Fabian Ziegenaus (IP), Gustav Schubert (regulatory, both Munich).

International lead: Travers Smith LLP

PR team


Private Equity
Mergers & Acquisitions

Share